Vivimed Labs Ltd
Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.[1]
- Market Cap ₹ 41.0 Cr.
- Current Price ₹ 4.95
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 21.3
- Dividend Yield 0.00 %
- ROCE -51.5 %
- ROE -163 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 0.23 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -30.9% over past five years.
- Promoter holding is low: 20.9%
- Company has a low return on equity of -43.7% over last 3 years.
- Contingent liabilities of Rs.123 Cr.
- Promoters have pledged 37.1% of their holding.
- Debtor days have increased from 110 to 150 days.
- Promoter holding has decreased over last 3 years: -7.64%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
668 | 1,109 | 1,351 | 1,380 | 1,346 | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 147 | |
538 | 916 | 1,139 | 1,156 | 1,111 | 1,057 | 971 | 1,135 | 1,049 | 830 | 245 | 374 | 317 | |
Operating Profit | 130 | 193 | 212 | 224 | 234 | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -169 |
OPM % | 20% | 17% | 16% | 16% | 17% | 28% | 18% | 14% | 1% | 4% | -3% | -100% | -115% |
3 | 12 | 8 | 6 | 11 | 8 | 10 | 23 | 8 | 10 | 1 | 1 | 3 | |
Interest | 28 | 48 | 67 | 86 | 84 | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 44 |
Depreciation | 27 | 59 | 66 | 66 | 61 | 58 | 56 | 67 | 67 | 56 | 18 | 108 | 110 |
Profit before tax | 78 | 98 | 87 | 78 | 100 | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -321 |
Tax % | 19% | 15% | 24% | 7% | 16% | 25% | 11% | 13% | -0% | 3% | 4% | -1% | |
63 | 84 | 66 | 72 | 84 | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -318 | |
EPS in Rs | 9.06 | 10.41 | 8.20 | 8.90 | 10.33 | 26.41 | 9.44 | 6.95 | -13.16 | -8.67 | -8.16 | -39.62 | -38.35 |
Dividend Payout % | 7% | 6% | 7% | 0% | 0% | 2% | 4% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -16% |
5 Years: | -31% |
3 Years: | -44% |
TTM: | -30% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -293% |
Stock Price CAGR | |
---|---|
10 Years: | -23% |
5 Years: | -20% |
3 Years: | -38% |
1 Year: | 0% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | -22% |
3 Years: | -44% |
Last Year: | -163% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 14 | 16 | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
Reserves | 328 | 427 | 478 | 479 | 505 | 718 | 885 | 602 | 493 | 415 | 348 | 23 | 160 |
695 | 729 | 958 | 1,076 | 1,015 | 1,011 | 1,149 | 1,280 | 1,268 | 326 | 359 | 379 | 320 | |
263 | 405 | 406 | 327 | 519 | 317 | 343 | 431 | 432 | 532 | 543 | 651 | 714 | |
Total Liabilities | 1,299 | 1,577 | 1,858 | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,069 | 1,210 |
595 | 709 | 808 | 813 | 814 | 879 | 1,035 | 965 | 1,045 | 502 | 520 | 436 | 522 | |
CWIP | 8 | 27 | 38 | 90 | 94 | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 |
Investments | 1 | 0 | 0 | 3 | 3 | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 192 |
695 | 840 | 1,011 | 992 | 1,144 | 1,104 | 1,290 | 1,239 | 990 | 529 | 507 | 414 | 476 | |
Total Assets | 1,299 | 1,577 | 1,858 | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,069 | 1,210 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
45 | 90 | -118 | 140 | 154 | 58 | 21 | 422 | 80 | 567 | 28 | 35 | |
-424 | -170 | -291 | -107 | -190 | -68 | -164 | -89 | -196 | 404 | -16 | -5 | |
404 | 67 | 419 | -42 | 41 | 35 | 186 | -338 | 72 | -1,015 | -10 | -34 | |
Net Cash Flow | 25 | -12 | 11 | -8 | 4 | 25 | 44 | -5 | -44 | -44 | 1 | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 121 | 101 | 94 | 87 | 88 | 50 | 85 | 99 | 86 | 46 | 134 | 150 |
Inventory Days | 268 | 247 | 249 | 244 | 294 | 329 | 411 | 397 | 396 | 263 | 573 | 216 |
Days Payable | 170 | 118 | 106 | 107 | 98 | 122 | 154 | 207 | 179 | 35 | 100 | 93 |
Cash Conversion Cycle | 220 | 230 | 237 | 224 | 285 | 258 | 342 | 288 | 303 | 274 | 607 | 273 |
Working Capital Days | 208 | 161 | 159 | 146 | 169 | 151 | 239 | 161 | 216 | 190 | 653 | 588 |
ROCE % | 14% | 13% | 12% | 11% | 12% | 22% | 9% | 7% | -3% | -1% | -3% | -52% |
Documents
Announcements
- Board Meeting Intimation for Notice Of Board Meeting / Closure Of Trading Window 23 Aug
- Results-Delay in Financial Results 22 Aug
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 16 Aug
- Shareholder Meeting / Postal Ballot-Outcome of EGM 14 Aug
- Notice Of The Extra-Ordinary General Meeting 20 Jul
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Aug 2019TranscriptNotesPPT
-
Mar 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Aug 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Aug 2016Transcript PPT
-
May 2016Transcript PPT
-
Aug 2015TranscriptNotesPPT
API Division (~69% of revenues)[1]
This is the flagship division of the company which is primarily managed by its subsidiary UQUIFA s.a. based in Spain. The division further has 2 sub-divisions :-[2]